54 related articles for article (PubMed ID: 38488807)
1. Molecular Heterogeneity in Leiomyosarcoma and Implications for Personalised Medicine.
Arfan S; Thway K; Jones RL; Huang PH
Curr Treat Options Oncol; 2024 May; 25(5):644-658. PubMed ID: 38656686
[TBL] [Abstract][Full Text] [Related]
2. Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling.
Beck AH; Lee CH; Witten DM; Gleason BC; Edris B; Espinosa I; Zhu S; Li R; Montgomery KD; Marinelli RJ; Tibshirani R; Hastie T; Jablons DM; Rubin BP; Fletcher CD; West RB; van de Rijn M
Oncogene; 2010 Feb; 29(6):845-54. PubMed ID: 19901961
[TBL] [Abstract][Full Text] [Related]
3. Stathmin is an Independent Prognostic Marker of Poor Outcome in Uterine Leiomyosarcoma.
Davidson B; Skeie-Jensen T; Holth A; Hausladen S
Int J Gynecol Pathol; 2024 Jun; ():. PubMed ID: 38847524
[TBL] [Abstract][Full Text] [Related]
4. Interrogating the Genomic Landscape of Uterine Leiomyosarcoma: A Potential for Patient Benefit.
Dall GV; Hamilton A; Ratnayake G; Scott C; Barker H
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326717
[TBL] [Abstract][Full Text] [Related]
5. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.
Tsuyoshi H; Yoshida Y
Cancer Sci; 2018 Jun; 109(6):1743-1752. PubMed ID: 29660202
[TBL] [Abstract][Full Text] [Related]
6. Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma.
Dermawan JK; Chiang S; Singer S; Jadeja B; Hensley ML; Tap WD; Movva S; Maki RG; Antonescu CR
Clin Cancer Res; 2024 May; 30(10):2260-2271. PubMed ID: 38488807
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma.
Hasan NM; Sharma A; Ruzgar NM; Deshpande H; Olino K; Khan S; Ahuja N
Oncotarget; 2021 Aug; 12(16):1566-1579. PubMed ID: 34381562
[TBL] [Abstract][Full Text] [Related]
8. Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile.
Astolfi A; Nannini M; Indio V; Schipani A; Rizzo A; Perrone AM; De Iaco P; Pirini MG; De Leo A; Urbini M; Secchiero P; Pantaleo MA
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751892
[TBL] [Abstract][Full Text] [Related]
9. HPV51-associated Leiomyosarcoma: A Novel Class of TP53/RB1-Wildtype Tumor With Predilection for the Female Lower Reproductive Tract.
Williams EA; Montesion M; Lincoln V; Tse JY; Hiemenz MC; Mata DA; Shah BB; Shoroye A; Alexander BM; Werth AJ; Foley-Peres K; Milante RR; Ross JS; Ramkissoon SH; Williams KJ; Adhikari LJ; Zuna RE; LeBoit PE; Lin DI; Elvin JA
Am J Surg Pathol; 2022 Jun; 46(6):729-741. PubMed ID: 35034043
[TBL] [Abstract][Full Text] [Related]
10.
Williams EA; Sharaf R; Decker B; Werth AJ; Toma H; Montesion M; Sokol ES; Pavlick DC; Shah N; Williams KJ; Venstrom JM; Alexander BM; Ross JS; Albacker LA; Lin DI; Ramkissoon SH; Elvin JA
JCO Precis Oncol; 2020; 4():. PubMed ID: 33015533
[TBL] [Abstract][Full Text] [Related]
11. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
Harold J; Bellone S; Manavella DD; Mutlu L; McNamara B; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MS; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2023 Jan; 168():157-165. PubMed ID: 36442427
[TBL] [Abstract][Full Text] [Related]
12. An interpretable AI model for recurrence prediction after surgery in gastrointestinal stromal tumour: an observational cohort study.
Bertsimas D; Margonis GA; Tang S; Koulouras A; Antonescu CR; Brennan MF; Martin-Broto J; Rutkowski P; Stasinos G; Wang J; Pikoulis E; Bylina E; Sobczuk P; Gutierrez A; Jadeja B; Tap WD; Chi P; Singer S
EClinicalMedicine; 2023 Oct; 64():102200. PubMed ID: 37731933
[TBL] [Abstract][Full Text] [Related]
13. Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era.
Dermawan JK; Kelly C; Gao Z; Smith S; Jadeja B; Singer S; Tap WD; Chi P; Antonescu CR
Clin Cancer Res; 2023 Oct; 29(19):3974-3985. PubMed ID: 37477937
[TBL] [Abstract][Full Text] [Related]
14. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets.
Nacev BA; Sanchez-Vega F; Smith SA; Antonescu CR; Rosenbaum E; Shi H; Tang C; Socci ND; Rana S; Gularte-Mérida R; Zehir A; Gounder MM; Bowler TG; Luthra A; Jadeja B; Okada A; Strong JA; Stoller J; Chan JE; Chi P; D'Angelo SP; Dickson MA; Kelly CM; Keohan ML; Movva S; Thornton K; Meyers PA; Wexler LH; Slotkin EK; Glade Bender JL; Shukla NN; Hensley ML; Healey JH; La Quaglia MP; Alektiar KM; Crago AM; Yoon SS; Untch BR; Chiang S; Agaram NP; Hameed MR; Berger MF; Solit DB; Schultz N; Ladanyi M; Singer S; Tap WD
Nat Commun; 2022 Jun; 13(1):3405. PubMed ID: 35705560
[TBL] [Abstract][Full Text] [Related]
15. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma.
Gounder MM; Agaram NP; Trabucco SE; Robinson V; Ferraro RA; Millis SZ; Krishnan A; Lee J; Attia S; Abida W; Drilon A; Chi P; Angelo SP; Dickson MA; Keohan ML; Kelly CM; Agulnik M; Chawla SP; Choy E; Chugh R; Meyer CF; Myer PA; Moore JL; Okimoto RA; Pollock RE; Ravi V; Singh AS; Somaiah N; Wagner AJ; Healey JH; Frampton GM; Venstrom JM; Ross JS; Ladanyi M; Singer S; Brennan MF; Schwartz GK; Lazar AJ; Thomas DM; Maki RG; Tap WD; Ali SM; Jin DX
Nat Commun; 2022 Jun; 13(1):3406. PubMed ID: 35705558
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
